Truist Financial Maintains Amgen(AMGN.US) With Hold Rating, Announces Target Price $298
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $324
RBC Trims Price Target on Amgen to $324 From $330, Keeps Outperform Rating
Piper Sandler Initiates Amgen(AMGN.US) With Buy Rating, Announces Target Price $310
Amgen Is Maintained at Overweight by Piper Sandler
Amgen Analyst Ratings
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $350
Jefferies Adjusts Amgen Price Target to $350 From $380, Maintains Buy Rating
UBS Cuts Price Target on Amgen to $280 From $326, Maintains Neutral Rating
Oppenheimer Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Oppenheimer Remains a Buy on Amgen (AMGN)
Amgen Analyst Ratings
Evercore Maintains Amgen(AMGN.US) With Buy Rating
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $383
TD Cowen Reaffirms Their Buy Rating on Amgen (AMGN)
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $360
Amgen Analyst Ratings
RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $330
BMO Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $362
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $383